Abstract 208P
Background
Germ cell tumours of testis is the most common cancer in young men in the western world. India has the lowest incidence globally and hence Indian data is sparse. We report the outcomes of patients with non-seminomatous germ cell tumours of testis treated at a tertiary cancer centre in South India over a period of ten years.
Methods
Patients with a histopathological diagnosis of non-seminomatous germ cell tumours of testis from Jan 1, 2006 to Dec 31, 2016 were included in the study. Patient demographics, tumour characteristics and treatment details were retrieved from case records. Kaplan-Meier method was used to estimate progression-free survival and overall survival. Cox regression model was used to analyse the prognostic factors.
Results
One hundred and nineteen patients with non-seminomatous germ cell tumours of testis of testis were included in the study. The median follow-up was 81 months. The estimated four-year overall survival and progression-free survival was 87.1% and 84.5% respectively. The four-year overall survival for good, intermediate and poor-risk groups was 93.6%,87.5% and for 52.6% respectively. The progression-free survival at four years was 91.4%, 87.8% and 47.4% for good, intermediate and poor-risk groups respectively. The presence of non-pulmonary visceral metastasis and biochemical response after chemotherapy were significant factors for overall survival and progression free survival in multivariate cox proportional hazards regression.
Conclusions
The survival figures are comparable to the rest of the world except in the poor prognostic risk group. The inferior survival noticed in this group of patients may be due to the lack of good salvage procedures. High dose chemotherapy with stem cell support may be considered more often for this group of patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
360P - Number of lymph nodes examined was not an independent risk factor for the survival of patients with stage IA1-2 lung adenocarcinoma undergoing sublobar resection
Presenter: Zhenbin Qiu
Session: e-Poster Display Session
361P - Radiomic model predicting radiological response after thoracic stereotactic body radiotherapy regardless of tumor histology and staging
Presenter: Ben Man Fei Cheung
Session: e-Poster Display Session
362P - Integrative and comparative genomic analysis and immune microenvironment features of lung cancer patients with tuberculosis
Presenter: Xiaoling Xu
Session: e-Poster Display Session
363P - Genetic predisposition for pre-invasive lung adenocarcinoma manifesting as ground-glass nodules with family history of lung cancer
Presenter: Rui Fu
Session: e-Poster Display Session
364P - A deep learning model for the classification of lung cancer
Presenter: Gouji Toyokawa
Session: e-Poster Display Session
365P - Utilization of on-site pathology evaluation for lung cancer diagnosis in the Philippines’ National University Hospital
Presenter: Rich Ericson King
Session: e-Poster Display Session
367P - Detection of epidermal growth factor receptor mutations (EGFR-mut) from cell-free DNA in pleural effusion (PE-DNA) of patients with non-small cell lung cancer (NSCLC)
Presenter: Kirsty Lee
Session: e-Poster Display Session
368P - Real-world characteristics, treatment, and outcomes of stage III non-small cell lung cancer in Japan: SOLUTION study
Presenter: Haruyasu Murakami
Session: e-Poster Display Session
369P - The surgical perspective in neoadjuvant immunotherapy for resectable non-small cell lung cancer
Presenter: Long Jiang
Session: e-Poster Display Session
371P - Real-world insights into treatment patterns and outcomes in stage III non-small cell lung cancer (NSCLC): KINDLE study India analysis
Presenter: Kumar Prabhash
Session: e-Poster Display Session